Nasdaq Affirms Delisting Decision for CERO Therapeutics, Forcing Move to OTC Markets
CERO sits 33% above its 52-week low of $0.037.
Summary
CERO Therapeutics announced that the Nasdaq Listing and Hearing Review Council affirmed the decision to delist its securities, effective January 29, 2026, following an appeal.
Key Events · Corporate Governance and Compliance · CERO
-
Nasdaq Council Affirms Delisting
On January 29, 2026, the Nasdaq Listing and Hearing Review Council affirmed the prior decision to delist the company's securities from Nasdaq.
-
Appeal Process Concluded
This decision concludes the company's appeal against the initial delisting determination received on October 29, 2025.
-
Transition to OTC Markets Expected
The delisting will likely result in the company's securities trading on over-the-counter markets, which typically entails lower liquidity and reduced investor visibility.
Analysis · CERO · Life Sciences
The Nasdaq Listing and Hearing Review Council has affirmed the decision to delist CERO Therapeutics' securities, effective January 29, 2026. This follows an initial delisting determination on October 29, 2025, which the company appealed. Delisting from a major exchange like Nasdaq is a critical negative event for a company, especially one with a micro-cap valuation. It typically leads to significantly reduced liquidity, diminished investor confidence, and a potential move to over-the-counter (OTC) markets, which can further complicate capital raising efforts and investor access. This event fundamentally alters the investment thesis for CERO Therapeutics.
At the time of this filing, CERO was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $1M. The 52-week trading range was $0.04 to $888.00. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.